RA CAPITAL MANAGEMENT, L.P. - 21 Jul 2023 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
ABOS
Transactions as of
21 Jul 2023
Net transactions value
+$39,999,998
Form type
4
Filing time
25 Jul 2023, 16:30:41 UTC
Previous filing
21 Jul 2023
Next filing
09 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Purchase $39,999,998 +5,161,290 +65% $7.75 13,043,179 21 Jul 2023 See Footnotes F1, F2, F3
holding ABOS Common Stock 1,300,034 21 Jul 2023 See Footnotes F3, F4
holding ABOS Common Stock 588,850 21 Jul 2023 See Footnotes F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 20, 2023.
F2 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4 Held directly by the Nexus Fund II.
F5 Held directly by the Account.

Remarks:

Ms. Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors.